Interesting that in today's presentation, which identifies the size of Rett populations in various nations/regions outside the US (Slide 12), Israel gets a mention despite having just 200 identified Rett patients.
Which makes me wonder whether an Israeli pharma might be in the mix of interested parties….
Israel’s leading and globally-known pharma is Teva Pharmaceuticals. It is headquartered in Tel Aviv but also listed on the NASDAQ. Its revenues are ~US$16bn p.a. and market cap is ~US$10 bn. It has facilities in Israel, North America, Europe (Teva Europe has 20,000 staff over 30 European countries), Australia, and South America but also has a foothold in China and Japan.
Teva develops, manufactures, and commercializes generic and specialty medicines, including specialty medicines to treat CNS disorders. For example, it has received FDA approval for orphan drugs, Austedo for the treatment of Tardive Dyskinesia and Huntington’s disease chorea in adults and Copaxone for relapsing MS.
Ann: Investor Presentation, 14 March 2023, page-21
-
- There are more pages in this discussion • 125 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$20.00 |
Change
0.090(0.45%) |
Mkt cap ! $2.556B | |||
| Open | High | Low | Value | Volume |
| $19.88 | $20.07 | $19.73 | $11.80M | 591.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 5901 | $19.97 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $20.00 | 3262 | 5 |
View Market Depth
| Last trade - 16.10pm 21/06/2024 (20 minute delay) ? |
| NEU (ASX) Chart |